ITM

Highly Engaged Employees

ITM stands as a prominent radiopharmaceutical biotech company, committed to developing and supplying a new generation of radiopharmaceutical therapeutics and diagnostics specifically for hard-to-treat tumors. The company's core mission is to address the critical needs of cancer patients, clinicians, and partners through exceptional development, production, and global distribution of medical radioisotopes. Driven by a principle of improved patient benefit, ITM actively advances a comprehensive precision oncology pipeline, featuring multiple Phase 3 studies. These studies integrate the company’s high-quality radioisotopes with a diverse array of targeting molecules, aiming to enhance treatment efficacy.

Leveraging two decades of pioneering radiopharma expertise, ITM has established a central industry position and a robust global network. This foundation enables the company to deliver more effective, targeted treatments designed to significantly improve clinical outcomes and patient quality of life. The company operates with a dedicated team focused on innovation and operational excellence, contributing to its mission of advancing cancer care. Meet ITM's team to gain insights into the expertise driving these advancements.

ITM reported a revenue of $230.6M and operates with an employee range of 500 - 1,000 individuals. The company has secured substantial funding, including significant rounds in recent years, underscoring investor confidence in its innovative approach and market potential. This financial backing supports its ongoing research and development efforts, particularly in advancing its precision oncology pipeline and expanding its global supply capabilities for critical medical radioisotopes. Explore financial highlights for detailed investment and revenue data.